PARIS--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority): Date Total Total number of voting rights number of outstanding shares April 40, 544, Theoretical number of voting rights: 30, 204 40, 544, 204 2015 (including treasury shares)Number of real voting rights: 40, 518, 878 (without treasury shares) About Onxeo Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Positive preliminary results of the Phase II trial in severe oral mucositis Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma For more information, visit the website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3 A %2F%2Fwww.onxeo.com&esheet=51106972&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=1&md5=4bd617a117e29237e2c300f8568c0971) Contacts: Onxeo Judith Greciet, CEO j.greciet@onxeo.com Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00 or Caroline Carmagnol, Alize RP onxeo@alizerp.com +33 6 64 18 99 59 / +33 1 44 54 36 62
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2015
| Source: Onxeo SA